D-0544-2025 Class II Ongoing
FDA drug recall D-0544-2025 was initiated by Pfizer Inc. on Jul 10, 2025 and is designated Class II. Reason for recall: CGMP Deviations; particulates identified during visual inspection The recall status is ongoing. Affected quantity: 50,855 2 mL vials.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 6, 2025
- Initiation Date
- Jul 10, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 50,855 2 mL vials
Product description
Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001. Made in Austria, Carton NDC - 60793-701-10, Syringe NDC - 60793-701-02
Reason for recall
CGMP Deviations; particulates identified during visual inspection
Distribution pattern
Nationwide in the USA
Code information
Lots: HJ3235, Exp 09/30/26; GL2954, HP6222, Exp, 01/31/27; HR9967, Exp 05/31/27; HP6232, LT5190,Exp 09/30/27; HP6228, Exp 10/31/27;
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0544-2025
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.